{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:32:22Z","timestamp":1789590742816,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>\n                    As rifampicin can cause the induction and inhibition of multiple metabolizing enzymes and transporters, it has been challenging to accurately predict the complex drug\u2013drug interactions (\n                    <jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>\n                    s). We previously constructed a physiologically\u2010based pharmacokinetic (\n                    <jats:styled-content style=\"fixed-case\">PBPK<\/jats:styled-content>\n                    ) model of rifampicin accounting for the components for the induction of cytochrome P450 (\n                    <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>\n                    ) 3A\/\n                    <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>\n                    2C9 and the inhibition of organic anion transporting polypeptide 1B (\n                    <jats:styled-content style=\"fixed-case\">OATP<\/jats:styled-content>\n                    1B). This study aimed to expand and verify the\n                    <jats:styled-content style=\"fixed-case\">PBPK<\/jats:styled-content>\n                    model for rifampicin by incorporating additional components for the induction of\n                    <jats:styled-content style=\"fixed-case\">OATP<\/jats:styled-content>\n                    1B and\n                    <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>\n                    2C8 and the inhibition of multidrug resistance protein 2. The established\n                    <jats:styled-content style=\"fixed-case\">PBPK<\/jats:styled-content>\n                    model was capable of accurately predicting complex rifampicin\u2010induced alterations in the profiles of glibenclamide, repaglinide, and coproporphyrin I (an endogenous biomarker of\n                    <jats:styled-content style=\"fixed-case\">OATP<\/jats:styled-content>\n                    1B activities) with various dosing regimens. Our comprehensive rifampicin\n                    <jats:styled-content style=\"fixed-case\">PBPK<\/jats:styled-content>\n                    model may enable quantitative prediction of\n                    <jats:styled-content style=\"fixed-case\">DDI<\/jats:styled-content>\n                    s across diverse potential victim drugs and endogenous biomarkers handled by multiple metabolizing enzymes and transporters.\n                  <\/jats:p>","DOI":"10.1002\/psp4.12457","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T02:38:05Z","timestamp":1566009485000},"page":"845-857","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Expanded Physiologically\u2010Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction"],"prefix":"10.1002","volume":"8","author":[{"given":"Ryuta","family":"Asaumi","sequence":"first","affiliation":[{"name":"Pharmacokinetic Research Laboratories Ono Pharmaceutical Co., Ltd. Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Menzel","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences Seoul National University Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken\u2010ichi","family":"Nunoya","sequence":"additional","affiliation":[{"name":"Pharmacokinetic Research Laboratories Ono Pharmaceutical Co., Ltd. Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Imawaka","sequence":"additional","affiliation":[{"name":"Pharmacokinetic Research Laboratories Ono Pharmaceutical Co., Ltd. Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacokinetics Graduate School of Pharmaceutical Sciences The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Sugiyama Laboratory RIKEN Baton Zone Program RIKEN Cluster for Science, Technology and Innovation Hub RIKEN Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b14-00767"},{"key":"e_1_2_10_3_1","volume-title":"In Vitro Metabolism\u2010 and Transporter\u2010 Mediated Drug\u2010Drug Interaction Studies Guidance for Industry: Draft Guidance","author":"Center for Drug Evaluation and Research","year":"2017"},{"key":"e_1_2_10_4_1","volume-title":"Guideline on the Investigation of Drug Interactions","author":"Committee for Human Medicinal Products","year":"2012"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12275"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1073"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12377"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1554-0"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.06.006"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.142"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01972.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2416-3"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.234914"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0648-3"},{"key":"e_1_2_10_15_1","unstructured":"US Food and Drug Administration.Drug approval package of Livalo\u00ae(pitavastatin)<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022363s000_ClinPharmR_P2.pdf>."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02515.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.10.003"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.05.001"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.186"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2168-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.070276"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0746-z"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003253704"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111183"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1013"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12343"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.391"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.04.063"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12348"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-010-9176-y"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920013804545124"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920007782109733"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023294632129"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061209"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.059105"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016089"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01124-13"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23876"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_157.x"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.037523"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1395"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8525"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12457","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.12457","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T13:43:34Z","timestamp":1694180614000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/psp4.12457"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12457","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"2019-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}